Platelet-Type Bleeding Disorder 15 and Thrombocytopenia via the ACTN1 Gene
Summary and Pricing
Test Method
Exome Sequencing with CNV DetectionTest Code | Test Copy Genes | Test CPT Code | Gene CPT Codes Copy CPT Code | Base Price | |
---|---|---|---|---|---|
12051 | ACTN1 | 81479 | 81479,81479 | $990 | Order Options and Pricing |
An additional 25% charge will be applied to STAT orders. STAT orders are prioritized throughout the testing process.
Click here for costs to reflex to whole PGxome (if original test is on PGxome Sequencing platform).
Click here for costs to reflex to whole PGnome (if original test is on PGnome Sequencing platform).
Turnaround Time
3 weeks on average for standard orders or 2 weeks on average for STAT orders.
Please note: Once the testing process begins, an Estimated Report Date (ERD) range will be displayed in the portal. This is the most accurate prediction of when your report will be complete and may differ from the average TAT published on our website. About 85% of our tests will be reported within or before the ERD range. We will notify you of significant delays or holds which will impact the ERD. Learn more about turnaround times here.
Targeted Testing
For ordering sequencing of targeted known variants, go to our Targeted Variants page.
Clinical Features and Genetics
Clinical Features
Inherited thrombocytopenias (IT) comprise a heterogeneous group of disorders characterized by platelet counts below the lower limit of normal, i.e. below 150,000/microL (150 x 109/L) in adults. Bleeding manifestations of thrombocytopenia range from mild to severe and may include excessive bruising (purpura), petechiae, prolonged bleeding from cuts or from surgical procedures, spontaneous nose bleeds, and in women, heavy menstrual flows. About half of ITs are syndromic disorders characterized by other physical and neurological anomalies, or immunodeficiencies (Balduini et al. 2013. PubMed ID: 23397552). Over 30 genes are known to be associated with ITs. Pathogenic variants in known genes are found in only about 50% of cases (Kunishima et al. 2006. PubMed ID: 16169642; Noris et al. 2017. PubMed ID: 29222283). Noris et al. divide ITs into three groups: forms characterized by only platelet deficiencies, syndromic ITs with additional congenital defects, and ITs associated with increased risk of developing additional disease such as myelodysplastic syndrome (MDS) and acute leukemia (AL) (Churpek et al. 2013. PubMed ID: 22691122). It is important to distinguish ITs from immune/idiopathic thrombocytopenias (ITP) in order to inform clinical management and identify potential at risk family members.
ACTN1-associated platelet-type bleeding disorder 15 is characterized by mild thrombocytopenia with large platelets (macrothrombocytopenia), low risk of bleeding, and anisocytosis (Kunishima et al. 2013. PubMed ID: 23434115). The prognosis for ACTN1-related thrombocytopenia diagnosis is considered good.
Genetics
ACTN1-associated macrothrombocytopenia is inherited in an autosomal dominant manner (Kunishima et al. 2013. PubMed ID: 23434115). Pathogenic variants in ACTN1 accounted for 5.5% of dominant thrombocytopenia cases in a study of Japanese individuals and are the fourth most frequent cause of inherited thrombocytopenias overall (Kunishima et al. 2013. PubMed ID: 23434115; Faleschini et al. 2018. PubMed ID: 30351444). Pathogenic variants consist primarily of missense variants (Westbury et al. 2015. PubMed ID: 25949529), and no gross deletions or duplications have been reported.
ACTN1 encodes a non-muscle isoforms of α-actinin 1 found in megakaryocytes and platelets. Pathogenic variants in the ACTN1 protein affect proper subcellular localization, which leads to abnormal cytoskeletal formation (Bottega et al. 2015. PubMed ID: 25361813).
Clinical Sensitivity - Sequencing with CNV PGxome
Over 30 genes are known to be associated with inherited thrombocytopenias. Pathogenic variants in known genes are found in only about 50% of cases (Kunishima and Saito. 2006. PubMed ID: 16169642; Noris et al. 2017. PubMed ID: 29222283). Pathogenic variants in ACTN1 accounted for 5.5% of dominant thrombocytopenia cases in a study of Japanese individuals and are the fourth most frequent cause of inherited thrombocytopenias overall (Kunishima et al. 2013. PubMed ID: 23434115; Faleschini et al. 2018. PubMed ID: 30351444).
Testing Strategy
Copy number variants (CNVs) are also detected from NGS data. We utilize a CNV-calling algorithm that compares mean read depth and distribution for each target in the test sample against multiple matched controls. Neighboring target read depth and distribution and zygosity of any variants within each target region are used to reinforce CNV calls. All CNVs are confirmed using another technology such as aCGH, MLPA, or PCR before they are reported.
This test provides full coverage of all coding exons of the ACTN1 gene plus 10 bases of flanking noncoding DNA in all available transcripts along with other non-coding regions in which pathogenic variants have been identified at PreventionGenetics or reported elsewhere. We define full coverage as >20X NGS reads or Sanger sequencing. PGnome panels typically provide slightly increased coverage over the PGxome equivalent. PGnome sequencing panels have the added benefit of additional analysis and reporting of deep intronic regions (where applicable).
Dependent on the sequencing backbone selected for this testing, discounted reflex testing to any other similar backbone-based test is available (i.e., PGxome panel to whole PGxome; PGnome panel to whole PGnome).
Indications for Test
Patients with abnormal platelet function, large platelets, and low platelet counts.
Patients with abnormal platelet function, large platelets, and low platelet counts.
Gene
Official Gene Symbol | OMIM ID |
---|---|
ACTN1 | 102575 |
Inheritance | Abbreviation |
---|---|
Autosomal Dominant | AD |
Autosomal Recessive | AR |
X-Linked | XL |
Mitochondrial | MT |
Disease
Name | Inheritance | OMIM ID |
---|---|---|
Bleeding Disorder, Platelet-Type, 15 | AD | 615193 |
Related Test
Name |
---|
Bleeding Disorders Panel |
Citations
- Balduini et al. 2013. PubMed ID: 23397552
- Bottega et al. 2015. PubMed ID: 25361813
- Churpek et al. 2013. PubMed ID: 22691122
- Faleschini et al. 2018. PubMed ID: 30351444
- Kunishima and Saito. 2006. PubMed ID: 16169642
- Kunishima et al. 2013. PubMed ID: 23434115
- Noris and Pecci. 2017. PubMed ID: 29222283
- Westbury et al. 2015. PubMed ID: 25949529
Ordering/Specimens
Ordering Options
We offer several options when ordering sequencing tests. For more information on these options, see our Ordering Instructions page. To view available options, click on the Order Options button within the test description.
myPrevent - Online Ordering
- The test can be added to your online orders in the Summary and Pricing section.
- Once the test has been added log in to myPrevent to fill out an online requisition form.
- PGnome sequencing panels can be ordered via the myPrevent portal only at this time.
Requisition Form
- A completed requisition form must accompany all specimens.
- Billing information along with specimen and shipping instructions are within the requisition form.
- All testing must be ordered by a qualified healthcare provider.
For Requisition Forms, visit our Forms page
If ordering a Duo or Trio test, the proband and all comparator samples are required to initiate testing. If we do not receive all required samples for the test ordered within 21 days, we will convert the order to the most effective testing strategy with the samples available. Prior authorization and/or billing in place may be impacted by a change in test code.
Specimen Types
Specimen Requirements and Shipping Details
PGxome (Exome) Sequencing Panel
PGnome (Genome) Sequencing Panel
ORDER OPTIONS
View Ordering Instructions1) Select Test Type
2) Select Additional Test Options
No Additional Test Options are available for this test.